Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) has received an average rating of "Moderate Buy" from the six brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $27.67.
Several brokerages recently commented on KMTS. Wolfe Research started coverage on Kestra Medical Technologies in a research note on Monday. They issued an "outperform" rating and a $29.00 price target on the stock. Bank of America began coverage on shares of Kestra Medical Technologies in a research note on Monday. They issued a "buy" rating and a $30.00 target price on the stock. Piper Sandler assumed coverage on shares of Kestra Medical Technologies in a research report on Monday. They set an "overweight" rating and a $27.00 target price for the company. Stifel Nicolaus started coverage on shares of Kestra Medical Technologies in a research report on Monday. They issued a "buy" rating and a $28.00 price target on the stock. Finally, Wells Fargo & Company initiated coverage on shares of Kestra Medical Technologies in a report on Monday. They set an "overweight" rating and a $28.00 price objective for the company.
View Our Latest Research Report on Kestra Medical Technologies
Kestra Medical Technologies Stock Down 6.5 %
NASDAQ KMTS traded down $1.68 during trading on Monday, reaching $24.02. 217,488 shares of the company traded hands, compared to its average volume of 285,081. Kestra Medical Technologies has a 1-year low of $20.00 and a 1-year high of $26.06.
About Kestra Medical Technologies
(
Get Free ReportWe are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Featured Articles
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
